GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

motugivatrep   Click here for help

GtoPdb Ligand ID: 14510

Synonyms: Avarept® | compound 1 [WO2024071349] | SJP-0132 | SJP0132
Approved drug
motugivatrep is an approved drug
Compound class: Synthetic organic
Comment: Motugivatrep (SJP-0132) is a selective transient receptor potential cation channel subfamily V member 1 (TRPV1) antagonist [3]. It was designed to ameliorate the signs and symptoms dry eye disease.
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 4
Hydrogen bond donors 2
Rotatable bonds 4
Topological polar surface area 58.56
Molecular weight 403.4
XLogP 1.73
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES C1=CC(=C2C[C@@H](CCC2=C1)O)NC(=O)/C=C/3\CCOC4=CC(=CC=C34)C(F)(F)F
Isomeric SMILES C1CC2=C(C[C@@H]1O)C(=CC=C2)NC(=O)/C=C/3\CCOC4=C3C=CC(=C4)C(F)(F)F
InChI InChI=1S/C22H20F3NO3/c23-22(24,25)15-5-7-17-14(8-9-29-20(17)11-15)10-21(28)26-19-3-1-2-13-4-6-16(27)12-18(13)19/h1-3,5,7,10-11,16,27H,4,6,8-9,12H2,(H,26,28)/b14-10+/t16-/m1/s1
InChI Key MAWBBYZCTDJMDD-HFQYIWAZSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
References
1. Hori Y, Wada T, Omatsu K, SJP-0132 clinical study investigators. (2026)
Efficacy and Safety of SJP-0132 in Patients With Dry Eye Disease: A Phase 2b Randomized, Double-Masked, Dose-Finding Study.
Am J Ophthalmol, 283: 163-175. [PMID:41352685]
2. Wada T, Omatsu K, Pflugfelder SC. (2026)
Results of a Randomized, Double-Masked, Placebo-Controlled Phase 1/2 Study of a TRPV1 Antagonist SJP-0132 in Participants With Dry Eye Disease.
Am J Ophthalmol, 284: 216-225. [PMID:41554419]
3. Yamashita Y. (2024)
Combination preparation containing heterocyclidene acetamide derivative.
Patent number: WO2024071349A1. Assignee: Senju Pharmaceutical Co Ltd, Mochida Pharmaceutical Co Ltd. Priority date: 08/09/2023. Publication date: 04/04/2024.